Checking more lymph nodes linked to cancer patient survival

Why do patients with gastric or pancreatic cancer live longer when they are treated at cancer centers or high-volume hospitals than patients treated at low-volume or community hospitals?

New research from Northwestern University’s Feinberg School of Medicine found that cancer patients have more lymph nodes examined for the spread of their disease if they are treated at hospitals performing more cancer surgeries or those designated as comprehensive cancer centers.

Lymph node metastases (indicating the spread of cancer) have been shown to predict patients’ prognosis after cancer tissue is removed from the stomach or pancreas. If too few lymph nodes are examined for malignant cells, a patient’s cancer may be incorrectly classified, which alters the prognosis, treatment decisions and eligibility for clinical trials.

“The differences in nodal evaluation may contribute to improved long-term outcomes at cancer centers and high-volume hospitals for patients with gastric and pancreatic cancer,” said Karl Bilimoria, M.D., lead author of the paper and a surgical resident at the Feinberg School. The study was published in the July issue of Archives of Surgery.

Current guidelines recommend evaluating at least 15 regional lymph nodes for gastric and pancreatic cancer, according to the study.

Researchers reported that patients at a high-volume hospital or a hospital designated as a National Cancer Institute comprehensive cancer center or as part of the National Comprehensive Cancer Network were more likely to have at least 15 lymph nodes evaluated than patients undergoing surgery at community or low-volume hospitals.

“Every reasonable attempt should be made to assess the optimal number of lymph nodes to accurately diagnose stage disease in patients with gastric and pancreatic cancer,” said Bilimoria, who also is a research fellow at the American College of Surgeons. “The status of patients’ lymph nodes is a powerful predictor of their outcome.”

###

Contact: Marla Paul
.(JavaScript must be enabled to view this email address)
312-503-8928
Northwestern University

Print Version
Tell-a-Friend comments powered by Disqus

RELATED ARTICLES:

New biomarkers may influence drug design and alternative treatments of cancer, study shows   Metabolic profiles distinguish early stage ovarian cancer with unprecedented accuracy   Moffitt researchers develop first genetic test to predict tumor sensitivity to radiation therapy   New drug for neuroblastoma shows promise in phase I study   Experimental treatment sends deadly leukemia into remission   Study could reduce unnecessary cancer screening   UA researchers discover component of cinnamon prevents colorectal cancer in mice   Profiling approach to enable right lung cancer treatment match   Fat grafting technique improves results of breast augmentation   Germline TP53 mutations in patients with early-onset colorectal cancer   Clinical trial suggests combination therapy is best for low-grade brain tumors   UW research shows sensor technology may help improve accuracy of clinical breast exams